Volume 30, Issue 3 (September 2026)
Physiol Pharmacol 2026, 30(3): 255-272 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Negareshifard P, Keshavarzi S, Habibian A, Bagheriha K, Banihashemian S Z, Bagheri B et al . Preclinical cardiovascular mechanisms of SGLT2 inhibitors in heart failure: evidence from in vivo and in vitro studies. Physiol Pharmacol 2026; 30 (3) :255-272
URL: http://ppj.phypha.ir/article-1-2564-en.html
URL: http://ppj.phypha.ir/article-1-2564-en.html
Paniz Negareshifard 
, Saeedeh Keshavarzi , Anoosha Habibian , Kosar Bagheriha , Seyedeh Zahra Banihashemian , Bahador Bagheri , Marzieh Noruzi 
, Saeedeh Keshavarzi , Anoosha Habibian , Kosar Bagheriha , Seyedeh Zahra Banihashemian , Bahador Bagheri , Marzieh Noruzi
Abstract: (845 Views)
Heart failure (HF) remains a major global health challenge, particularly among aging populations and patients with type 2 diabetes (T2D). Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents, have demonstrated significant cardiovascular benefits in patients with HF regardless of diabetic status. The reviewed studies indicate that SGLT2 inhibitors may exert cardioprotective effects through the attenuation of oxidative stress, inflammation, mitochondrial dysfunction, apoptosis, and cardiac fibrosis. Several studies have shown that modulation of signaling pathways involving NADPH oxidases, Sirtuin 1, AMPK, and STAT3 contributes to reducing myocardial injury and adverse cardiac remodeling. These findings suggest that the cardiovascular benefits of SGLT2 inhibitors extend beyond glycemic control and may directly influence molecular pathways involved in HF progression.
In conclusion, the reviewed evidence suggests that SGLT2 inhibitors play an important role in attenuating oxidative stress, improving cardiac function, and slowing the progression of heart failure through multiple cardioprotective mechanisms. These findings also highlight that SGLT2 inhibitors may have potential implications for the prevention of cardiovascular diseases and provide important directions for future research.
Type of Manuscript: Review |
Subject:
Cardiovascular Physiology/Pharmacology
References
1. Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos C H, Varela A, et al. Empagliflozin Limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Frontiers in Physiology 2017; 8: 1077. [DOI:10.3389/fphys.2017.01077]
2. Badreldin H, Elshal M, El-Karef A, Ibrahim T. Empagliflozin protects the heart from atrial fibrillation in rats through inhibiting the NF-κB/HIF-1α regulatory axis and atrial remodeling. International Immunopharmacology 2024; 143: 113403. [DOI:10.1016/j.intimp.2024.113403]
3. Bedard K, Krause K H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews 2007; 87: 245-313. [DOI:10.1152/physrev.00044.2005]
4. Boulet J, Sridhar V S, Bouabdallaoui N, Tardif J-C, White M. Inflammation in heart failure: pathophysiology and therapeutic strategies. Inflammation Research 2024; 73: 709-723. [DOI:10.1007/s00011-023-01845-6]
5. Butts B, Gary R A, Dunbar S B, Butler J. The Importance of NLRP3 Inflammasome in Heart Failure. Journal of Cardiac Failure 2015; 21: 586-593. [DOI:10.1016/j.cardfail.2015.04.014]
6. Cai C, Guo Z, Chang X, Li Z, Wu F, He J, et al. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway. Redox Biology 2022; 52: 102288. [DOI:10.1016/j.redox.2022.102288]
7. Chambers JM, Croteau D, Pimentel DR, Gower AC, Panagia M, Baka T, Qin F, Luptak I, Colucci WS. SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gαq-mice. J Mol Cell Cardiol Plus. 2025 Apr 9;12:100296. [DOI:10.1016/j.jmccpl.2025.100296]
8. Chen R, Xu M, Hogg R T, Li J, Little B, Gerard R D, et al. The acetylase/deacetylase couple CREB-binding protein/Sirtuin 1 controls hypoxia-inducible factor 2 signaling. Journal of Biological Chemistry 2012; 287: 30800-30811. [DOI:10.1074/jbc.M111.244780]
9. Chen S, Coronel R, Hollmann M W, Weber N C, Zuurbier C J. Direct cardiac effects of SGLT2 inhibitors. Cardiovascular Diabetology 2022; 21: 45. [DOI:10.1186/s12933-022-01480-1]
10. Chung C-C, Lin Y-K, Chen Y-C, Kao Y-H, Yeh Y-H, Trang N N, et al. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis. Cardiovascular Diabetology 2023; 22: 27. [DOI:10.1186/s12933-023-01756-0]
11. Cinti F, Laborante R, Cappannoli L, Morciano C, Gugliandolo S, Pontecorvi A, et al. The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction? Cardiovascular Diabetology 2025; 24: 208. [DOI:10.1186/s12933-025-02767-9]
12. Cowie M R, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology 2020; 17: 761-772. [DOI:10.1038/s41569-020-0406-8]
13. Crispino S P, Segreti A, Nafisio V, Valente D, Crisci F, Ferro A, et al. The role of SGLT2-inhibitors across all stages of heart failure and mechanisms of early clinical benefit: from prevention to advanced heart failure. Biomedicines 2025; 13: 608. [DOI:10.3390/biomedicines13030608]
14. Croteau D, Luptak I, Chambers J M, Hobai I, Panagia M, Pimentel D R, et al. Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice. Journal of the American Heart Association 2021; 10: e019995. [DOI:10.1161/JAHA.120.019995]
15. Currie S, Loughrey C M, Craig M A, Smith G L. Calcium/calmodulin-dependent protein kinase IIdelta associates with the ryanodine receptor complex and regulates channel function in rabbit heart. Biochemical Journal 2004; 377: 357-366. [DOI:10.1042/bj20031043]
16. Duan H-Y, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovascular Diabetology 2024; 23: 252. [DOI:10.1186/s12933-024-02312-0]
17. Dunlay S M, Givertz M M, Aguilar D, Allen L A, Chan M, Desai A S, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019; 140: e294-e324. [DOI:10.1161/CIR.0000000000000691]
18. Durak A, Olgar Y, Degirmenci S, et al. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovascular Diabetology 2018; 17:144. [DOI:10.1186/s12933-018-0790-0]
19. Erickson J R, Pereira L, Wang L, Han G, Ferguson A, Dao K, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 2013; 502: 372-6. [DOI:10.1038/nature12537]
20. Fedacko J, Tuppo E E, Singh R B, Elkilany G N, Hristova K. Chapter 2 - Epidemiology and mortality due to heart failure. In: Singh RB, Fedacko J, Hristova K and Elkilany GN, editors. Pathophysiology, risk factors, and management of chronic heart failure: Academic Press, 2024: 23-40. [DOI:10.1016/B978-0-12-822972-9.00017-1]
21. Forstermann U, Sessa W C. Nitric oxide synthases: regulation and function. European Heart Journal 2012; 33: 829-837, 837a-837d. [DOI:10.1093/eurheartj/ehr304]
22. Harhous Z, Booz G W, Ovize M, Bidaux G, Kurdi M. An update on the multifaceted roles of STAT3 in the heart. Frontiers in Cardiovascular Medicine 2019; 6: 150. [DOI:10.3389/fcvm.2019.00150]
23. He L, Ma S, Zuo Q, Zhang G, Wang Z, Zhang T, et al. An effective sodium-dependent glucose transporter 2 inhibition, canagliflozin, prevents development of hypertensive heart failure in dahl salt-sensitive rats. Frontiers in Pharmacology 2022; 13: 856386. [DOI:10.3389/fphar.2022.856386]
24. Heidenreich P A, Bozkurt B, Aguilar D, Allen L A, Byun J J, Colvin M M, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology 2022; 79: e263-e421. [DOI:10.1161/CIR.0000000000001063]
25. Hoong C W, Chua M W. SGLT2 inhibitors as calorie restriction mimetics: insights on longevity pathways and age-related diseases. Endocrinology 2021; 162: bqab079. [DOI:10.1210/endocr/bqab079]
26. Hudmon A, Schulman H, Kim J, Maltez J M, Tsien R W, Pitt G S. CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation. Journal of Cell Biology 2005; 171: 537-47. [DOI:10.1083/jcb.200505155]
27. Huo J-L, Feng Q, Pan S, Fu W-J, Liu Z, Liu Z. Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. Cell Death Discovery 2023; 9: 256. [DOI:10.1038/s41420-023-01553-4]
28. Kenny H C, Abel E D. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circulation Research 2019; 124: 121-141. [DOI:10.1161/CIRCRESAHA.118.311371]
29. Khan M S, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nature Reviews Cardiology 2024; 21: 717-734. [DOI:10.1038/s41569-024-01046-6]
30. Kim S R, Lee S G, Kim S H, Kim J H, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nature Communications 2020; 11: 2127. [DOI:10.1038/s41467-020-15983-6]
31. Kitasato L, Murayama Y, Ishizue N, Kobayashi S, Oikawa J, Fukaya H, et al. Canagliflozin restores electrical properties and suppresses structural damage in isoproterenol-induced myocardial injury models. Scientific Reports 2025; 15: 44958. [DOI:10.1038/s41598-025-29126-8]
32. Komaniecka N, Maroszek S, Drozdzik M, Oswald S, Drozdzik M. Transporter proteins as therapeutic drug targets-with a focus on SGLT2 inhibitors. International Journal of Molecular Sciences 2024; 25: 6926. [DOI:10.3390/ijms25136926]
33. Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis C P, Polkinghorne M, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal 2021; 42: 4947-4960. [DOI:10.1093/eurheartj/ehab420]
34. Koniari I, Velissaris D, Kounis N G, Koufou E, Artopoulou E, de Gregorio C, et al. Anti-diabetic therapy, heart failure and oxidative stress: an update. Journal of Clinical Medicine 2022; 11. [DOI:10.3390/jcm11164660]
35. Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik T J. NADPH oxidases in vascular pathology. Antioxid Redox Signal 2014; 20: 2794-2814. [DOI:10.1089/ars.2013.5607]
36. Lee C-C, Chen W-T, Chen S-Y, Lee T-M. Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts. Biochemical Pharmacology 2021; 192: 114674. [DOI:10.1016/j.bcp.2021.114674]
37. Lee H-C, Shiou Y-L, Jhuo S-J, Chang C-Y, Liu P-L, Jhuang W-J, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovascular Diabetology 2019; 18: 45. [DOI:10.1186/s12933-019-0849-6]
38. Lee T M, Chang N C, Lin S Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology and Medicine 2017; 104: 298-310. [DOI:10.1016/j.freeradbiomed.2017.01.035]
39. Li X, Flynn E R, do Carmo J M, Wang Z, da Silva A A, Mouton A J, et al. Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure. Frontiers in Cardiovascular Medicine 2022; 9: 859253. [DOI:10.3389/fcvm.2022.859253]
40. Li X, Wang M, Kalina J-O, Preckel B, Hollmann M W, Albrecht M, et al. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis. Redox Biology 2024; 69: 102979. [DOI:10.1016/j.redox.2023.102979]
41. Lin Y-H, Tsai W-C, Chiu C-C, Chi N-Y, Liu Y-H, Huang T-C, et al. The beneficial effect of the SGLT2 inhibitor dapagliflozin in alleviating acute myocardial infarction-induced cardiomyocyte injury by increasing the sirtuin family SIRT1/SIRT3 and cascade signaling. International Journal of Molecular Sciences 2024; 25: 8541. [DOI:10.3390/ijms25158541]
42. Lopaschuk G D, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (sglt2) inhibitors: a perspective. JACC: Basic to Translational Science 2020; 5: 632-644. [DOI:10.1016/j.jacbts.2020.02.004]
43. Lu Q, Li X, Liu J, Sun X, Rousselle T, Ren D, et al. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Bioscience Reports 2019; 39: BSR20181995. [DOI:10.1042/BSR20181995]
44. Lu Q, Liu J, Li X, Sun X, Zhang J, Ren D, et al. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway. Molecular and Cellular Endocrinology 2020; 501: 110642. [DOI:10.1016/j.mce.2019.110642]
45. Luo B, Huang F, Liu Y, Liang Y, Wei Z, Ke H, et al. NLRP3 inflammasome as a molecular marker in diabetic cardiomyopathy. Frontiers in Physiology 2017; 8: 519. [DOI:10.3389/fphys.2017.00519]
46. Ma S, He L-L, Zhang G-R, Zuo Q-J, Wang Z-L, Zhai J-L, et al. Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction. Naunyn-schmiedeberg’s Archives of Pharmacology 2022; 395: 945-962. [DOI:10.1007/s00210-022-02243-1]
47. Ma S, He L, Zuo Q, Zhang G, Guo Y. Canagliflozin regulates ferroptosis, potentially via activating AMPK/PGC-1α/Nrf2 signaling in HFpEF Rats. Cardiovascular Innovations and Applications 2023; 7: 987. [DOI:10.15212/CVIA.2022.0024]
48. Maack C, Lehrke M, Backs J, Heinzel F R, Hulot J-S, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. European Heart Journal 2018; 39: 4243-4254. [DOI:10.1093/eurheartj/ehy596]
49. Mangmool S, Shukla A K, Rockman H A. β-Arrestin-dependent activation of Ca2+/calmodulin kinase II after β1-adrenergic receptor stimulation. Journal of Cell Biology 2010; 189: 573-587. [DOI:10.1083/jcb.200911047]
50. Marwick T H, Ritchie R, Shaw J E, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. Journal of the American College of Cardiology 2018; 71: 339-351. [DOI:10.1016/j.jacc.2017.11.019]
51. McDonagh T A, Metra M, Adamo M, Gardner R S, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2023; 44: 3627-3639. [DOI:10.1093/eurheartj/ehad195]
52. Meza C A, La Favor J D, Kim D-H, Hickner R C. Endothelial dysfunction: is there a hyperglycemia-induced imbalance of NOX and NOS? International Jurnal of Molecular Sciences 2019; 20: 3775. [DOI:10.3390/ijms20153775]
53. Moellmann J, Mann P A, Kappel B A, Kahles F, Klinkhammer B M, Boor P, et al. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes, Obesity and Metabolism 2022; 24: 2263-2272. [DOI:10.1111/dom.14814]
54. Mylonas N, Nikolaou P-E, Efentakis P, Dimitriadis G, Iliodromitis E, Andreadou I. Comparative study on the cardioprotective effects against ischemia/reperfusion injury of the selective SGLT2 inhibitors, empagliflozin, dapagliflozin and ertugliflozin in non-diabetic mice. European Heart Journal 2021; 42: ehab724. 3250. [DOI:10.1093/eurheartj/ehab724.3250]
55. Nikolaou P E, Efentakis P, Abu Qourah F, Femminò S, Makridakis M, Kanaki Z, et al. Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxidants & Redox Signaling 2021; 34: 551-571. [DOI:10.1089/ars.2019.7923]
56. Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled? Current Heart Failure Reports 2021; 18: 315-328. [DOI:10.1007/s11897-021-00529-8]
57. Packer M. Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circulation: Heart Failure 2020; 13: e007197. [DOI:10.1161/CIRCHEARTFAILURE.120.007197]
58. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation 2022; 146: 1383-1405. [DOI:10.1161/CIRCULATIONAHA.122.061732]
59. Palmiero G, Cesaro A, Vetrano E, Pafundi P C, Galiero R, Caturano A, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. International Journal of Molecular Sciences 2021; 22: 5863. [DOI:10.3390/ijms22115863]
60. Pham L T T, Mangmool S, Parichatikanond W. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: guardians against mitochondrial dysfunction and endoplasmic reticulum stress in heart diseases. ACS Pharmacology & Translational Science 2024; 7: 3279-3298. [DOI:10.1021/acsptsci.4c00240]
61. Piccirillo F, Lanciotti M, Nusca A, Frau L, Spanò A, Liporace P, et al. Sodium-glucose transporter-2 inhibitors (SGLT2i) and myocardial ischemia: another compelling reason to consider these agents regardless of diabetes. International Journal of Molecular Sciences 2025; 26: 2103. [DOI:10.3390/ijms26052103]
62. Picht E, DeSantiago J, Huke S, Kaetzel M A, Dedman J R, Bers D M. CaMKII inhibition targeted to the sarcoplasmic reticulum inhibits frequency-dependent acceleration of relaxation and Ca2+ current facilitation. Journal of Molecular and Cellular Cardiology 2007; 42: 196-205. [DOI:10.1016/j.yjmcc.2006.09.007]
63. Pickering R J, Rosado C J, Sharma A, Buksh S, Tate M, de Haan J B. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical & Translational Immunology 2018; 7: e1016. [DOI:10.1002/cti2.1016]
64. Piperis C, Marathonitis A, Anastasiou A, Theofilis P, Mourouzis K, Giannakodimos A, et al. Multifaceted impact of SGLT2 inhibitors in heart failure patients: exploring diverse mechanisms of action. Biomedicines 2024; 12: 2314. [DOI:10.3390/biomedicines12102314]
65. Prosser B L, Ward C W, Lederer W. X-ROS signaling: rapid mechano-chemo transduction in heart. Science 2011; 333: 1440-1445. [DOI:10.1126/science.1202768]
66. Read A, Schröder M. The unfolded protein response: an overview. Biology 2021; 10: 384. [DOI:10.3390/biology10050384]
67. Ritchie R H, Abel E D. Basic mechanisms of diabetic heart disease. Circulation research 2020; 126: 1501-1525. [DOI:10.1161/CIRCRESAHA.120.315913]
68. Roe N D, Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascular Pharmacology 2012; 57: 168-72. [DOI:10.1016/j.vph.2012.02.004]
69. Rolski F, Mączewski M. Cardiac Fibrosis: Mechanistic discoveries linked to SGLT2 inhibitors. Pharmaceuticals 2025; 18: 313. [DOI:10.3390/ph18030313]
70. Sato T, Takeda N. The roles of HIF-1α signaling in cardiovascular diseases. Journal of Cardiology 2023; 81: 202-208. [DOI:10.1016/j.jjcc.2022.09.002]
71. Sayour AA, Korkmaz-Icöz S, Loganathan S, Ruppert M, Sayour VN, Oláh A, Benke K, Brune M, Benkő R, Horváth EM, Karck M. Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. Journal of Translational Medicine 2019. 17(1), 127. [DOI:10.1186/s12967-019-1881-8]
72. Schönenberger M J, Krek W, Kovacs W J. EPAS1/HIF-2α is a driver of mammalian pexophagy. Autophagy 2015; 11: 967-969. [DOI:10.1080/15548627.2015.1045180]
73. Schwinger R H G. Pathophysiology of heart failure. Cardiovascular Diagnosis and Therapy 2021; 11: 263-276. [DOI:10.21037/cdt-20-302]
74. Sciarretta S, Forte M, Frati G, Sadoshima J. The complex network of mTOR signalling in the heart. Cardiovascular Research 2022; 118: 424-439. [DOI:10.1093/cvr/cvab033]
75. Semenza G. Regulation of metabolism by hypoxia-inducible factor 1. In Cold Spring Harbor symposia on quantitative biology, vol. 76, pp. 347-353. Cold Spring Harbor Laboratory Press, 2011. [DOI:10.1101/sqb.2011.76.010678]
76. Shi L, Zhu D, Wang S, Jiang A, Li F. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. American Journal of Hypertension 2019; 32: 452-459. [DOI:10.1093/ajh/hpz016]
77. Silter M, Kögler H, Zieseniss A, Wilting J, Schäfer K, Toischer K, et al. Impaired Ca 2+-handling in HIF-1α+/− mice as a consequence of pressure overload. Pflügers Archiv-European Journal of Physiology 2010; 459: 569-577. [DOI:10.1007/s00424-009-0748-x]
78. Sun H, Du B, Fu H, Yue Z, Wang X, Yu S, et al. Canagliflozin combined with aerobic exercise protects against chronic heart failure in rats. Iscience 2024; 27. [DOI:10.1016/j.isci.2024.109014]
79. Tan Y, Zhang Z, Zheng C, Wintergerst K A, Keller B B, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nature Reviews Cardiology 2020; 17: 585-607. [DOI:10.1038/s41569-020-0339-2]
80. Tanno M, Kuno A, Horio Y, Miura T. Emerging beneficial roles of sirtuins in heart failure. Basic Research in Cardiology 2012; 107: 273. [DOI:10.1007/s00395-012-0273-5]
81. Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nature Reviews Cardiology 2024; 21: 219-237. [DOI:10.1038/s41569-023-00946-3]
82. Tsai K-L, Hsieh P-L, Chou W-C, Cheng H-C, Huang Y-T, Chan S-H. Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. Cell & Bioscience 2021; 11: 44. [DOI:10.1186/s13578-021-00547-y]
83. Tsui J, Inagaki M, Schulman H. Calcium/calmodulin-dependent protein kinase II (CaMKII) localization acts in concert with substrate targeting to create spatial restriction for phosphorylation. Journal of Biological Chemistry 2005; 280: 9210-6. [DOI:10.1074/jbc.M407653200]
84. Uthman L, Homayr A, Juni RP, Spin EL, Kerindongo R, Boomsma M, Hollmann MW, Preckel B, Koolwijk P, van Hinsbergh VW, Zuurbier CJ. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells. Cellular Physiology and Biochemistry 2019; 53: 865-886. [DOI:10.33594/000000178]
85. Vafiadaki E, Sanoudou D, Arvanitis D A, Catino D H, Kranias E G, Kontrogianni-Konstantopoulos A. Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. Journal of Molecular Biology 2007; 367: 65-79. [DOI:10.1016/j.jmb.2006.10.057]
86. Varzideh F, Kansakar U, Wilson S, Jankauskas S S, Santulli G. The SGLT2 inhibitor canagliflozin attenuates mitochondrial oxidative stress and alterations of calcium handling induced by high glucose in human cardiac fibroblasts. Cell Cycle 2024; 23: 923-930. [DOI:10.1080/15384101.2025.2492423]
87. Wang X, Zhang G, Dasgupta S, Niewold E L, Li C, Li Q, et al. ATF4 protects the heart from failure by antagonizing oxidative stress. Circulation Research 2022; 131: 91-105. [DOI:10.1161/CIRCRESAHA.122.321050]
88. Wei H, Bedja D, Koitabashi N, Xing D, Chen J, Fox-Talbot K, et al. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-beta signaling. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: E841-850. [DOI:10.1073/pnas.1202081109]
89. Wichaiyo S, Saengklub N. Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence? Heart Failure Reviews 2022; 27: 1973-1990. [DOI:10.1007/s10741-022-10220-2]
90. Wu Y, MacMillan L B, McNeill R B, Colbran R J, Anderson M E. CaM kinase augments cardiac L-type Ca2+ current: a cellular mechanism for long Q-T arrhythmias. American Physiological 1999; 276: H2168-2178. [DOI:10.1152/ajpheart.1999.276.6.H2168]
91. Xiang D, Liu Y, Zhou S, Zhou E, Wang Y. Protective effects of estrogen on cardiovascular disease mediated by oxidative stress. Oxidative Medicine and Cellular Longevity 2021; 2021: 5523516. [DOI:10.1155/2021/5523516]
92. Xiong W, Xiong N, Wu Y, Sui Y, Xiao M, Qi X, et al. Canagliflozin alleviates pressure overload-induced cardiac dysfunction via PINK1 regulation by inhibiting mitophagy-driven ferroptosis. Canadian Journal of Cardiology 2026. [DOI:10.1016/j.cjca.2026.04.015]
93. Yang J, Li L, Zheng X, Lu Z, Zhou H. Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway. Biomedicine & Pharmacotherapy 2023; 165: 115125. [DOI:10.1016/j.biopha.2023.115125]
94. Yaribeygi H, AU - Butler A E, AU - Barreto G E. Antioxidative mechanisms of SGLT2 inhibitors in cardiometabolic complications. Experimental Physiology 2019; 104: 243-249.
95. Yu H, Han Z, Chang W, Zhou H, Du B, Jia B, et al. Canagliflozin ameliorates myocardial fibrosis and cardiac function in chronic heart failure: a dose-independent therapeutic approach. Journal of Cellular and Molecular Medicine 2025; 29: e70718. [DOI:10.1111/jcmm.70718]
96. Yu Y-W, Que J-Q, Liu S, Huang K-Y, Qian L, Weng Y-B, et al. Sodium-glucose co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Frontiers in Cardiovascular Medicine 2022; 8: 768214. [DOI:10.3389/fcvm.2021.768214]
97. Yuan X, Pan L, Zhang C, Zhu Q, Huang Z, Qin Y, et al. Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway. Frontiers in Pharmacology 2024; 15: 1499542. [DOI:10.3389/fphar.2024.1499542]
98. Zhang J, Chen X, Lv S, Hao Q. Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway. PLOS One 2025; 20: e0317295. [DOI:10.1371/journal.pone.0317295]
99. Zhang N, Feng B, Ma X, Sun K, Xu G, Zhou Y. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular Diabetology 2019; 18: 107. [DOI:10.1186/s12933-019-0914-1]
100. Zhang R, Xie Q, Lu X, Fan R, Tong N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 2024; 16: 99. [DOI:10.1186/s13098-024-01325-9]
101. Zhang T, Maier L S, Dalton N D, Miyamoto S, Ross Jr J, Bers D M, et al. The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circulation Research 2003; 92: 912-919. [DOI:10.1161/01.RES.0000069686.31472.C5]
102. Zhou L, Liu Y, Wang Z, Liu D, Xie B, Zhang Y, et al. Activation of NADPH oxidase mediates mitochondrial oxidative stress and atrial remodeling in diabetic rabbits. Life Sciences 2021; 272: 119240. [DOI:10.1016/j.lfs.2021.119240]
103. Zou R, Shi W, Qiu J, Zhou N, Du N, Zhou H, et al. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. Cardiovascular Diabetology 2022; 21: 106. [DOI:10.1186/s12933-022-01532-6]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
